Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE)Devaki Shilpa Surasi, Morand Piert, Brian F. Chapin et al.|European Urology|2023Cited by 90
Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancerJacob Taylor, Yair Lotan, Ashish M. Kamat et al.|British Journal of Urology|2024Cited by 27
Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Guérin Unresponsive Non–muscle-invasive Bladder Cancer Undergoing Bladder-sparing TherapiesDrupad Annapureddy, Yair Lotan, Jacob Taylor et al.|European Urology Focus|2025Cited by 2
NATURAL HISTORY OF BLADDER-SPARING THERAPY IN PATIENTS WITH BCG-UNRESPONSIVE DISEASE; RESULTS FROM A LARGE MULTI-CENTER COHORTJacob Taylor, William C. Huang, Drupad Annapureddy et al.|Urologic Oncology Seminars and Original Investigations|2024Cited by 1
ONCOLOGIC OUTCOMES OF GEMCITABINE-DOCETAXEL COMBINATION INTRAVESICAL BLADDER SPARING THERAPY COMPARED TO UPFRONT RADICAL CYSTECTOMY IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCERDrupad Annapureddy, William C. Huang, Jacob Taylor et al.|Urologic Oncology Seminars and Original Investigations|2024Cited by 1